Name of Journal: *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 46062

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective study***

Appropriate number of biliary biopsies and endoscopic retrograde cholangiopancreatography sessions for diagnosing biliary tract cancer

Takagi T *et al.* Appropriate endoscopic biliary biopsy

Tadayuki Takagi, Mitsuru Sugimoto, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Mika Takasumi, Minami Hashimoto, Takuto Hikichi, Hiromasa Ohira

**Tadayuki Takagi, Mitsuru Sugimoto, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Mika Takasumi, Minami Hashimoto, Hiromasa Ohira,** Department of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima 960-1247, Japan

**Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Mika Takasumi, Minami Hashimoto, Hiromasa Ohira,** Department of Endoscopy, Fukushima Medical University Hospital, Fukushima 960-1247, Japan

**ORCID number:** Tadayuki Takagi (0000-0003-0696-5973); Mitsuru Sugimoto (0000-0002-4223-613X); Rei Suzuki (0000-0002-4049-0484); Naoki Konno (0000-0001-9830-4317); Hiroyuki Asama (0000-0002-0102-0404); Yuki Sato (0000-0001-8000-0972); Hiroki Irie (0000-0002-4805-6244); Ko Watanabe (0000-0003-3895-7636); Jun Nakamura (0000-0001-6006-1778); Hitomi Kikuchi (0000-0003-0583-1623); Mika Takasumi (0000-0002-6025-8084); Minami Hashimoto (0000-0002-5750-7182); Takuto Hikichi (0000-0002-9815-1557); Hiromasa Ohira (0000-0003-4331-0634).

**Author contributions:** Takagi T and Sugimoto M designed and performed the study; Takagi T, Sugimoto M and Ohira H analyzed the data and wrote the paper; Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Sato Y, Hashimoto M and Hikichi T provided clinical advice; and Hikichi T and Ohira H supervised the study.

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of Fukushima Medical University.

**Informed consent statement:** Patients were not required to give informed consent for participation in the study because the analysis used anonymous clinical data obtained after each patient provided written consent agreeing to treatment. For full disclosure, the details of the study are published on the home page of Fukushima Medical University.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Mitsuru Sugimoto, MD, PhD, Assistant Professor,** Department of Gastroenterology, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, Fukushima 960-1247, Japan. [kita335@fmu.ac.jp](mailto:kita335@fmu.ac.jp)

**Telephone:** +81-24-5471202

**Fax:** +81-24-5472055

**Received:** January 26, 2019

**Peer-review started:** January 27, 2019

**First decision:** February 20, 2019

**Revised:** February 28, 2019

**Accepted:** March 11, 2019

**Article in press:** March 11, 2019

**Published online:** March 16, 2019

**Abstract**

***BACKGROUND***

Biliary ductal cancer (BDC) is a lethal disease; however, diagnosing BDC is challenging. Biliary biopsies are performed to pathologically diagnose BDC, but the appropriate parameters for biliary biopsy [number of biliary biopsies, number of endoscopic retrograde cholangiopancreatography (ERCP) sessions, *etc*.] are unknown.

***AIM***

To clarify what constitutes an adequate method for biliary biopsy.

***METHODS***

In total, 95 patients who underwent endoscopic biliary biopsy without choledochoscopy and who were pathologically diagnosed with BDC were enrolled in this study. The patients were divided into two groups. Seventy-six patients who were diagnosed by biliary biopsy were defined as the positive group (P group), and nineteen patients who were not diagnosed by biliary biopsy were defined as the negative group (N group). The patient characteristics and ERCP-related procedures were compared between the P and N groups.

***RESULTS***

The numbers of ERCP sessions and biliary biopsies were significantly different between the two groups [ERCP sessions (one/two), P group 72/4 *vs* N group 15/4, *p* value = 0.048; number of biliary biopsies, P group 2 (1-6) *vs* N group 2 (1-7), *p* value = 0.039]. In a multivariate analysis, fewer than 2 ERCP sessions was an independent factor influencing the positivity of the biliary biopsies.

***CONCLUSION***

This study clarified that ERCP and biliary ductal biopsy should only be performed once. If biliary cancer is not pathologically diagnosed after the first ERCP session, other methods (endoscopic ultrasonography-guided fine needle aspiration or choledochoscopy-guided biliary ductal biopsy) should be employed.

**Key words:** biliary ductal cancer; biliary biopsy; endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography-guided fine needle aspiration; choledochoscopy

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The appropriate parameters for biliary biopsy [number of biliary biopsies, number of endoscopic retrograde cholangiopancreatography (ERCP) sessions, *etc*.) are unknown. In this report, fewer than 2 ERCP sessions was an independent factor influencing the positivity of the biliary biopsies. If biliary cancer is not pathologically diagnosed after the first ERCP session, other methods (endoscopic ultrasonography-guided fine needle aspiration or choledochoscopy-guided biliary ductal biopsy) should be employed.

Citation: Takagi T, Sugimoto M, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, Kikuchi H, Takasumi M, Hashimoto M, Hikichi T, Ohira H. Appropriate number of biliary biopsies and endoscopic retrograde cholangiopancreatography sessions for diagnosing biliary tract cancer. *World J Gastrointest Endosc* 2019; 11(3): 231-238

URL: https://www.wjgnet.com/1948-5190/full/v11/i3/231.htm

DOI: https://dx.doi.org/10.4253/wjge.v11.i3.231

**INTRODUCTION**

Biliary ductal cancer (BDC) is a lethal disease; however, diagnosing BDC is challenging. The pathological diagnostic methods for BDC are biliary cytology, biliary brush cytology, and biliary biopsy by endoscopic retrograde cholangiopancreatography (ERCP).

The sensitivity of biliary cytology for diagnosing malignant biliary strictures is reported to be 32%-57%[1-9], and the sensitivity of biliary brush cytology is 33%-58%[3,4,10,11]. The sensitivity of biliary biopsy for diagnosing malignant biliary strictures is reported to be 36%-81%[3,4,7,9,11-13]. All reports except two indicate that the sensitivity of biliary biopsy is less than 65%. The sensitivities of biliary brush cytology and biliary biopsy are 61%-70.4%[4,11]. In addition, the sensitivity of repeated biliary cytology by endoscopic nasobiliary drainage tube is reported to be 72.4%[14].

Of these procedures for diagnosing BDC, the appropriate method of biliary biopsy is not clearly defined. In particular, the correct number of biliary biopsies is unknown, as is whether additional ERCP sessions are appropriate if the first session does not result in the pathological diagnosis of BDC. Therefore, the aim of this study was to clarify the appropriate parameters for biliary biopsy for the diagnosis of BDC.

**MATERIALS AND METHODS**

***Ethics***

This study was a retrospective study conducted to determine the adequate parameters for biliary biopsy used to diagnose BDC. Informed consent was not required for this study because the analysis utilized anonymous clinical data that were obtained after each patient agreed to treatment by providing written informed consent. This study was approved by the Institutional Review Board of Fukushima Medical University.

***Subjects and methods of diagnosing BDC***

We enrolled 95 patients who underwent endoscopic biliary biopsy without choledochoscopy and who were pathologically diagnosed with BDC between February 2007 and March 2018. These patients underwent ERCP and biliary cytology or brush cytology and biliary biopsy. If they were not diagnosed by ERCP-related procedures, they were diagnosed by endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA), biopsy from duodenal invasion, or biopsy using choledochoscopy. The patients were divided into two groups. Seventy-six patients who were diagnosed by biliary biopsy were defined as the positive group (P group). Nineteen patients who were not diagnosed by biliary biopsy were defined as the negative group (N group).

***Procedures for endoscopic biliary biopsy***

In all patients, an endoscope was inserted after they were sufficiently sedated with midazolam. After the endoscope reached the descending part of the duodenum, the biliary cannulation was started. If the biliary cannulation was successful, bile was collected for biliary cytology. After a range of malignant biliary strictures were confirmed by cholangiography, endoscopic sphincterotomy (EST) or intraductal ultrasonography, biliary brush cytology was performed if deemed appropriate. At this stage, biliary biopsy was performed to diagnose the malignancy or the status of BDC progression. The number of biliary biopsies was determined randomly by each endoscopist. The collection of a sufficient specimen was visually confirmed. If a patient had already received a biliary stent, the stent was removed before biliary cannulation. In five patients, endoscopic nasobiliary drainage (ENBD) was performed. The bile that was used for cytology was turned in the pathological department twice a day for three days. JF260V, JF240, and TJF240 ERCP endoscopes (Olympus, Tokyo, Japan) were used. An MTW ERCP catheter taper (MTW Endoskopie, Wesel, Germany), Tandem XL (Boston Scientific Japan, Tokyo, Japan) or PR-233Q (Olympus) was used as the ERCP catheter. A Clever Cut 3V or an RX Needle Knife (Boston Scientific Japan, Tokyo, Japan) were used for endoscopic sphincterotomy (EST). An Endo Jaw FB231K (Olympus) or a Radial JawTM 4 Biopsy Forceps (Boston Scientific Japan) was used for the biliary biopsy (Figure 1). If the biliary stricture was too tight to allow the insertion of the Radial Jaw, a SpyBite (Boston Scientific Japan, Tokyo, Japan) was used for the biliary biopsy. Reverse α-type or α-type ENBD catheters (Gadelius Medical, Tokyo, Japan) or a FleximaTM Nasobiliary Catheter single pigtail (Olympus) was used for the ENBD catheter. The choledochoscope used in this study was a SpyGlass DSTM (Boston Scientific Japan).

***Examined items***

Patient characteristics (age, gender, receipt of antithrombotic drugs, location of tumor, Union for International Cancer Control (UICC) stage, cholangitis within the last month) and ERCP-related procedures (number of ERCP sessions; diagnosability of BDC from bile, brush cytology or ENBD cytology; EST; cup diameter of biopsy forceps (1 mm or 2 mm); total biopsy number; biopsy number before biliary stenting; biopsy number after biliary stenting; adverse events; post-ERCP pancreatitis (PEP)) were compared between the P group and the N group. Cholangitis was diagnosed according to the presence of an elevated white blood cell (WBC) count or C-reactive protein (CRP) level (WBC ≥ 10000/μl or CRP ≥ 5 mg/dl). The biopsy number was defined as the number of biopsies taken from the main stricture of the biliary cancer minus the number of screening and mapping biopsies. PEP was diagnosed by the presence of hyperamylasemia more than three times the normal level more than 24 hours after ERCP and abdominal pain[15]. In addition, we confirmed peripancreatic inflammation by contrast CT imaging in all PEP patients. The seriousness of PEP was determined according to the consensus guidelines proposed by Cotton *et al*[15] (mild: planned hospitalization was prolonged by 2-3 d, moderate: planned hospitalization was prolonged by 4-10 d, severe: planned hospitalization was prolonged by more than 10 d, a pseudocyst was present, intervention (percutaneous drainage or surgery) was necessary, or hemorrhagic pancreatitis developed).

***Statistical analyses***

The Mann-Whitney *U* test was used for the comparisons of continuous and ordinal variables. Fisher’s exact test was used for the comparisons of nominal variables. Multivariate logistic regression analysis was used. A *p* value < 0.05 was considered statistically significant. All statistical analyses were performed using the EZR platform (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, EZR is a modified version of R commander that was designed to perform functions that are frequently used in biostatistics[16].

**RESULTS**

Regarding patient characteristics, no items except age were significantly different between the P group and N group (Table 1). Age was significantly higher in the P group than in the N group [P group 75 (29 - 90) years *vs* N group 68 (43-82) years, *p* value = 0.012; median (range)].

Regarding ERCP-related procedures, the number of ERCP sessions and the total number of biopsies were significantly different between the two groups (ERCP session (one/two), P group 72/4 *vs* N group 15/4, *p* value = 0.048; total number of biopsies, P group 2 (1-6) *vs* N group 2 (1-7), *p* value = 0.039) (Table 2).

In univariate analysis, only fewer than two ERCP sessions significantly influenced the positivity of biliary biopsies (Table 3). In multivariate analysis including two factors (total number of biopsies ≤ 1, number of ERCP sessions < 2; the *p* values of these two factors were lower than the others in univariate analysis), fewer than two ERCP sessions was the independent factor influencing the positivity of biliary biopsies (Table 4).

**DISCUSSION**

In this study, we verified an adequate method of biliary biopsy for the diagnosis of BDC. Although the number of biliary biopsies did not affect the positivity of the biliary biopsies, it was revealed that multiple ERCP sessions for the diagnosis of BDC were not useful. If the result of the biliary biopsy is negative after the first ERCP session, other methods should be subsequently employed.

In past reports, EUS-FNA and choledochoscopy were introduced as additional methods. The efficacy of EUS-FNA for diagnosing malignant biliary strictures was reported in previous studies. The sensitivity of EUS-FNA for the diagnosis of malignant biliary strictures is 45%-94.0% with a specificity of 77%-100% and an accuracy of 68%-94.0%[17-23]. Ohshima *et al*[24] reported that 10 bile duct cancer cases not diagnosed by ERCP (brush cytology and biopsy) were successfully diagnosed by EUS-FNA. Nayar *et al*[25] and DeWitt *et al*[23] reported that EUS-FNA was successful after poor results were obtained with ERCP-related diagnostic methods. In addition, malignant lymph node swelling in pancreaticobiliary tract cancers were successfully diagnosed by EUS-FNA[26,27].

Starting approximately ten years ago, SpyGlass® (Boston Scientific Japan, Tokyo, Japan) has been increasingly used as the preferred choledochoscope. SpyGlass® was introduced in 2006 and is a very thin reusable fiber that is used with a disposable delivery catheter (SpyScope®, Boston Scientific Japan, Tokyo, Japan), which can be moved in four directions. The SpyGlass® system can be controlled by a single operator. In a systematic review by Navaneethan *et al*[28], the sensitivity and specificity of biliary biopsy with the SpyGlass® system were 74.7% and 93.3%, respectively, for the diagnosis of malignant biliary strictures that had previously failed to be diagnosed by brushings or biopsy[28-32]. In addition, a patient with an indeterminate biliary stricture who was not diagnosed by ERCP (brush cytology, intraductal biopsy) or EUS-FNA was diagnosed with cholangiocarcinoma by SpyGlass®-guided biopsy[33]. Recently, an advanced version of SpyGlass®, SpyGlass® DS (Boston Scientific Japan, Tokyo, Japan), was released. The image transmitted by SpyGlass® DS is clearer than the image transmitted by the original SpyGlass®, and the delivery system for SpyGlass® DS is easier to operate than that of SpyGlass®. The efficacy of SpyGlass® DS-guided biliary biopsy for the diagnosis of malignant biliary strictures that remained undiagnosed by previous brush cytology, biliary biopsy or EUS-FNA has been reported[34,35].

Then, the diagnostic methods used in the 19 patients in the N group were considered; 10 patients were diagnosed via surgery, 4 were diagnosed after bile cytology, 2 were diagnosed via biliary brush cytology, 1 was diagnosed through choledochoscopy-guided biopsy, 1 was diagnosed via EUS-FNA of metastatic lymph nodes, and 1 was diagnosed via a biopsy from duodenal invasion. Bile cytology and biliary brush cytology were performed with biliary biopsy. In addition, 3 of the 4 patients who underwent 2 sessions of ERCP remained undiagnosed before surgery. Therefore, other methods, such as EUS-FNA or choledochoscopy-guided biliary biopsy, should be performed if biliary cancer is not diagnosed in the first ERCP session.

This study had some limitations. First, this study was performed with a small sample size and at a single institution. Thus, a statistical bias might exist. Second, this study was retrospective. Therefore, the indications regarding the volumes of the specimens sampled by biliary biopsies were absent except for visually confirming the presence of a sufficient specimen. In the future, a larger sample size and prospective multicenter study are needed. Third, the volumes of the specimens sampled by biliary biopsy were not assessed. The correlation between the pathological diagnosis and the volume of biliary cancer specimens should be verified.

in conclusion, this study clarified that ERCP for biliary ductal biopsy should only be performed once. If biliary cancer is not pathologically diagnosed after the first session of ERCP, other methods (EUS-FNA or choledochoscopy-guided biliary ductal biopsy) should be employed.

**ARTICLE HIGHLIGHTS**

***Research background***

Biliary ductal cancer (BDC) is a lethal disease; however, the histological diagnosis of BDC is difficult.

***Research motivation***

Histological diagnosis of BDC is achieved by endoscopic biliary biopsy except for surgery. However, the appropriate method (*i.e*., the number of times, the number of ERCP sessions) for biliary biopsy is unknown.

***Research objectives***

This study aims to clarify the appropriate method of endoscopic biliary biopsy.

***Research methods***

The subjects of this study were patients who were histologically diagnosed with BDC. The patients who could be diagnosed by biliary biopsy were determined as the positive group (P group), and the patients who could not be diagnosed by biliary biopsy were determined as the negative group (N group). The methods for ERCP procedures were compared between the P group and the N group.

***Research results***

Multiple ERCP sessions did not contribute to the improvement of the diagnosability of biliary biopsy.

***Research conclusions***

If biliary cancer is not pathologically diagnosed after the first session of ERCP, other methods should be employed.

***Research perspectives***

From the results of this study, several methods will be developed and tested for diagnosing BDC.

**ACKNOWLEDGMENTS**

We are grateful to the staff at the Department of Gastroenterology, Fukushima Medical University, School of Medicine; the medical staff at the Department of Endoscopy, Fukushima Medical University Hospital; and the medical staff at the Gastroenterology Ward at Fukushima Medical University Hospital.

**REFERENCES**

1 **Foutch PG**, Kerr DM, Harlan JR, Kummet TD. A prospective, controlled analysis of endoscopic cytotechniques for diagnosis of malignant biliary strictures. *Am J Gastroenterol* 1991; **86**: 577-580 [PMID: 2028947]

2 **Lee JG**, Leung JW, Baillie J, Layfield LJ, Cotton PB. Benign, dysplastic, or malignant--making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. *Am J Gastroenterol* 1995; **90**: 722-726 [PMID: 7733076]

3 **Ponchon T**, Gagnon P, Berger F, Labadie M, Liaras A, Chavaillon A, Bory R. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. *Gastrointest Endosc* 1995; **42**: 565-572 [PMID: 8674929 DOI: 10.1016/S0016-5107(95)70012-9]

4 **Pugliese V**, Conio M, Nicolò G, Saccomanno S, Gatteschi B. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. *Gastrointest Endosc* 1995; **42**: 520-526 [PMID: 8674921 DOI: 10.1016/S0016-5107(95)70004-8]

5 **Glasbrenner B**, Ardan M, Boeck W, Preclik G, Möller P, Adler G. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. *Endoscopy* 1999; **31**: 712-717 [PMID: 10604612 DOI: 10.1055/s-1999-73]

6 **Mansfield JC**, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. *Gut* 1997; **40**: 671-677 [PMID: 9203949 DOI: 10.1136/gut.40.5.671]

7 **Jailwala J**, Fogel EL, Sherman S, Gottlieb K, Flueckiger J, Bucksot LG, Lehman GA. Triple-tissue sampling at ERCP in malignant biliary obstruction. *Gastrointest Endosc* 2000; **51**: 383-390 [PMID: 10744806 DOI: 10.1016/S0016-5107(00)70435-4]

8 **Macken E**, Drijkoningen M, Van Aken E, Van Steenbergen W. Brush cytology of ductal strictures during ERCP. *Acta Gastroenterol Belg* 2000; **63**: 254-259 [PMID: 11189981]

9 **Sugiyama M**, Atomi Y, Wada N, Kuroda A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. *Am J Gastroenterol* 1996; **91**: 465-467 [PMID: 8633492]

10 **Howell DA**, Parsons WG, Jones MA, Bosco JJ, Hanson BL. Complete tissue sampling of biliary strictures at ERCP using a new device. *Gastrointest Endosc* 1996; **43**: 498-502 [PMID: 8726766 DOI: 10.1016/S0016-5107(96)70294-8]

11 **Schoefl R**, Haefner M, Wrba F, Pfeffel F, Stain C, Poetzi R, Gangl A. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. *Scand J Gastroenterol* 1997; **32**: 363-368 [PMID: 9140159 DOI: 10.3109/00365529709007685]

12 **Kubota Y**, Takaoka M, Tani K, Ogura M, Kin H, Fujimura K, Mizuno T, Inoue K. Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. *Am J Gastroenterol* 1993; **88**: 1700-1704 [PMID: 8213710]

13 **Rösch T**, Hofrichter K, Frimberger E, Meining A, Born P, Weigert N, Allescher HD, Classen M, Barbur M, Schenck U, Werner M. ERCP or EUS for tissue diagnosis of biliary strictures? A prospective comparative study. *Gastrointest Endosc* 2004; **60**: 390-396 [PMID: 15332029 DOI: 10.1016/S0016-5107(04)01732-8]

14 **Uchida N**, Kamada H, Ono M, Aritomo Y, Masaki T, Nakatsu T, Kuriyama S. How many cytological examinations should be performed for the diagnosis of malignant biliary stricture via an endoscopic nasobiliary drainage tube? *J Gastroenterol Hepatol* 2008; **23**: 1501-1504 [PMID: 18028351 DOI: 10.1111/j.1440-1746.2007.05214.x]

15 **Cotton PB**, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointest Endosc* 1991; **37**: 383-393 [PMID: 2070995 DOI: 10.1016/S0016-5107(91)70740-2]

16 **Kanda Y**. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant* 2013; **48**: 452-458 [PMID: 23208313 DOI: 10.1038/bmt.2012.244]

17 **Matsubayashi H**, Matsui T, Yabuuchi Y, Imai K, Tanaka M, Kakushima N, Sasaki K, Ono H. Endoscopic ultrasonography guided-fine needle aspiration for the diagnosis of solid pancreaticobiliary lesions: Clinical aspects to improve the diagnosis. *World J Gastroenterol* 2016; **22**: 628-640 [PMID: 26811612 DOI: 10.3748/wjg.v22.i2.628]

18 **Lee JH**, Salem R, Aslanian H, Chacho M, Topazian M. Endoscopic ultrasound and fine-needle aspiration of unexplained bile duct strictures. *Am J Gastroenterol* 2004; **99**: 1069-1073 [PMID: 15180727 DOI: 10.1111/j.1572-0241.2004.30223.x]

19 **Byrne MF**, Gerke H, Mitchell RM, Stiffler HL, McGrath K, Branch MS, Baillie J, Jowell PS. Yield of endoscopic ultrasound-guided fine-needle aspiration of bile duct lesions. *Endoscopy* 2004; **36**: 715-719 [PMID: 15280978 DOI: 10.1055/s-2004-825657]

20 **Meara RS**, Jhala D, Eloubeidi MA, Eltoum I, Chhieng DC, Crowe DR, Varadarajulu S, Jhala N. Endoscopic ultrasound-guided FNA biopsy of bile duct and gallbladder: analysis of 53 cases. *Cytopathology* 2006; **17**: 42-49 [PMID: 16417564 DOI: 10.1111/j.1365-2303.2006.00319.x]

21 **Tummala P**, Munigala S, Eloubeidi MA, Agarwal B. Patients with obstructive jaundice and biliary stricture ± mass lesion on imaging: prevalence of malignancy and potential role of EUS-FNA. *J Clin Gastroenterol* 2013; **47**: 532-537 [PMID: 23340062 DOI: 10.1097/MCG.0b013e3182745d9f]

22 **Weilert F**, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. *Gastrointest Endosc* 2014; **80**: 97-104 [PMID: 24559784 DOI: 10.1016/j.gie.2013.12.031]

23 **DeWitt J**, Misra VL, Leblanc JK, McHenry L, Sherman S. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. *Gastrointest Endosc* 2006; **64**: 325-333 [PMID: 16923477 DOI: 10.1016/j.gie.2005.11.064]

24 **Ohshima Y**, Yasuda I, Kawakami H, Kuwatani M, Mukai T, Iwashita T, Doi S, Nakashima M, Hirose Y, Asaka M, Moriwaki H. EUS-FNA for suspected malignant biliary strictures after negative endoscopic transpapillary brush cytology and forceps biopsy. *J Gastroenterol* 2011; **46**: 921-928 [PMID: 21526370 DOI: 10.1007/s00535-011-0404-z]

25 **Nayar MK**, Manas DM, Wadehra V, Oppong KE. Role of EUS/EUS-guided FNA in the management of proximal biliary strictures. *Hepatogastroenterology* 2011; **58**: 1862-1865 [PMID: 22234054 DOI: 10.5754/hge10531]

26 **Gleeson FC**, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, Papachristou GI, Takahashi N, Rosen CB, Gores GJ. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. *Gastrointest Endosc* 2008; **67**: 438-443 [PMID: 18061597 DOI: 10.1016/j.gie.2007.07.018]

27 **Kurita A**, Kodama Y, Nakamoto Y, Isoda H, Minamiguchi S, Yoshimura K, Kuriyama K, Sawai Y, Uza N, Hatano E, Uemoto S, Togashi K, Haga H, Chiba T. Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer. *Gastrointest Endosc* 2016; **84**: 467-475.e1 [PMID: 26970011 DOI: 10.1016/j.gie.2016.02.045]

28 **Navaneethan U**, Hasan MK, Lourdusamy V, Njei B, Varadarajulu S, Hawes RH. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. *Gastrointest Endosc* 2015; **82**: 608-14.e2 [PMID: 26071061 DOI: 10.1016/j.gie.2015.04.030]

29 **Ramchandani M**, Reddy DN, Gupta R, Lakhtakia S, Tandan M, Darisetty S, Sekaran A, Rao GV. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. *Gastrointest Endosc* 2011; **74**: 511-519 [PMID: 21737076 DOI: 10.1016/j.gie.2011.04.034]

30 **Manta R**, Frazzoni M, Conigliaro R, Maccio L, Melotti G, Dabizzi E, Bertani H, Manno M, Castellani D, Villanacci V, Bassotti G. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: a single-center, prospective, cohort study. *Surg Endosc* 2013; **27**: 1569-1572 [PMID: 23233008 DOI: 10.1007/s00464-012-2628-2]

31 **Siddiqui AA**, Mehendiratta V, Jackson W, Loren DE, Kowalski TE, Eloubeidi MA. Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. *Clin Gastroenterol Hepatol* 2012; **10**: 466-71; quiz e48 [PMID: 22178463 DOI: 10.1016/j.cgh.2011.12.021]

32 **Nishikawa T**, Tsuyuguchi T, Sakai Y, Sugiyama H, Miyazaki M, Yokosuka O. Comparison of the diagnostic accuracy of peroral video-cholangioscopic visual findings and cholangioscopy-guided forceps biopsy findings for indeterminate biliary lesions: a prospective study. *Gastrointest Endosc* 2013; **77**: 219-226 [PMID: 23231758 DOI: 10.1016/j.gie.2012.10.011]

33 **Figueroa Marrero A**, Chavarría-Herbozo CM, de la Serna Higuera C, Pérez-Miranda M. Long-standing indeterminate biliary stricture with iterative negative tissue sampling revealed as cholangiocarcinoma under SpyGlassTM cholangiocoscopy. *Rev Esp Enferm Dig* 2017; **109**: 220-221 [PMID: 28256149]

34 **Tanaka R**, Itoi T, Honjo M, Tsuchiya T, Kurihara T, Tsuji S, Tonozuka R, Kamada K, Sofuni A, Mukai S. New digital cholangiopancreatoscopy for diagnosis and therapy of pancreaticobiliary diseases (with videos). *J Hepatobiliary Pancreat Sci* 2016; **23**: 220-226 [PMID: 26822740 DOI: 10.1002/jhbp.328]

35 **Varadarajulu S**, Bang JY, Hasan MK, Navaneethan U, Hawes R, Hebert-Magee S. Improving the diagnostic yield of single-operator cholangioscopy-guided biopsy of indeterminate biliary strictures: ROSE to the rescue? (with video). *Gastrointest Endosc* 2016; **84**: 681-687 [PMID: 27048973 DOI: 10.1016/j.gie.2016.03.1497]

**P-Reviewer:** Fogli L, Lee CL **S-Editor:** Gong ZM

**L-Editor:** A **E-Editor:** Wu YXJ

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Comparison of patient characteristics between the positive group and the negative group**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **P group (*n* = 76)** | **N group (*n* = 19)** | ***P* value** |
| Age (yr) | 75 (29-90) | 68 (43-82) | 0.012 |
| Males | 60 (78.9) | 12 (63.2) | 0.229 |
| Received antithrombotic drugs | 14 (18.4) | 0 (0) | 0.064 |
| Location of tumor (distal/hilar) | 45/31 | 8/11 | 0.205 |
| UICC stage (1/2/3/4) | 27/29/10/10 | 7/7/3/2 | 0.91 |
| Cholangitis within the last month | 10 (13.2) | 3 (15.8) | 0.719 |

The values are shown as the median (range) or *n* (%). P: positive; N: negative; UICC: Union for International Cancer Control.

**Table 2 Comparison of endoscopic retrograde cholangiopancreatography -related procedures between the positive group and the negative group**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **P group (*n* = 76)** | **N group (*n* = 19)** | ***P* value** |
| Number of ERCP sessions (1/2) | 72/4 | 15/4 | 0.048 |
| EST | 74 (97.4) | 17 (89.5) | 0.177 |
| Diagnosability of bile or brush or ENBD cytology | 16/681 (23.5) | 5/19 (26.3) | 0.77 |
| Cup diameter of biopsy forceps (1 mm/2 mm) | 8/68 | 2/17 | 1.0 |
| Total number of biopsies | 2 (1 - 6) | 2 (1 - 7) | 0.039 |
| Number of biopsies before biliary stenting | 2 (1 - 4) | 2 (1 - 3) | 0.119 |
| Number of biopsies after biliary stenting | 2 (1 - 4) | 1 (1 - 6) | 0.065 |
| PEP | 4 (5.3) | 0 (0) | 0.58 |
| Moderate | 2 |  |  |
| Severe | 2 |  |  |

1Biliary cytology, brush cytology and endoscopic nasobiliary drainage cytology were not performed in 8 patients in the P group. The values are shown as median (range) or *n* (%). ERCP: endoscopic retrograde cholangiopancreatography; P: positive; N: negative; EST: endoscopic sphincterotomy; ENBD: endoscopic nasobiliary drainage; PEP: post-ERCP pancreatitis.

**Table 3 Univariate analysis of biliary biopsy positivity**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **P group (*n* = 76)** | **N group (*n* = 19)** | ***P* value** |
| Total number of biopsies ≤ 1 | 32 (42.1) | 4 (21.1) | 0.116 |
| Total number of biopsies ≤ 2 | 62 (81.6) | 12 (63.1) | 0.120 |
| Total number of biopsies ≤ 3 | 69 (90.8) | 15 (78.9) | 0.222 |
| Number of ERCP sessions < 2 | 72 (94.7) | 15 (78.9) | 0.048 |





The values are shown as *n* (%). P: positive; N: negative; ERCP: endoscopic retrograde cholangiopancreatography.

**Table 4 Multivariate stepwise analysis of biliary biopsy positivity**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **OR** | **95%CI** | ***P* value** |
| Number of ERCP sessions < 2 | 4.8 | 1.08-21.4 | 0.04 |

OR: odds ratio; CI: confidential interval; ERCP: endoscopic retrograde cholangiopancreatography.

**Figure 1** **Biliary biopsy forceps and the procedural steps of biliary biopsies.** A: Radial JawTM 4 Biopsy Forceps. The cup diameter of these forceps is 2 mm. b: The image perspective in cholangiography. Biliary biopsy was performed with a Radial JawTM 4. C: The specimen was obtained with 2-mm biopsy forceps (X 200, hematoxylin eosin (HE) staining). Papillate lines were formed by biliary cancer cells. D: SpyBite. The cup diameter of these forceps is 1 mm. E: Biliary biopsy was performed with the SpyBite system through the MTW endoscopic retrograde cholangiopancreatography (ERCP) catheter (arrow: the tip of a SpyBite, arrowhead: the tip of an MTW ERCP catheter). F: The specimen was obtained by 1-mm biopsy forceps (X 400, HE stain). Papillate lines were formed by columnar biliary cancer cells.



**a**

**b**

**d**

**e**

**f**

**c**